用于白内障手术瞳孔散大的托吡卡胺和去氧肾上腺素的安全性。
Safety of tropicamide and phenylephrine in pupillary mydriasis for cataract surgery.
作者信息
K Lodhi Sikander A, Ramsali Manjula V, Kulkarni Dilip K, Surender P, Murty Srinivasa
机构信息
Department of Ophthalmology, Malla Reddy Medical College for Women, Hyderabad, Telangana, India.
Department of Anaesthesiology, Malla Reddy Medical College for Women, Hyderabad, Telangana, India.
出版信息
Saudi J Ophthalmol. 2022 Feb 18;35(2):108-111. doi: 10.4103/1319-4534.337859. eCollection 2021 Apr-Jun.
PURPOSE
A prospective study to evaluate the adverse cardiovascular effects of topical phenylephrine and tropicamide used for pupillary mydriasis before cataract surgery.
METHODS
A total of 517 consecutive eyes in 517 patients subjected to routine 0.8% tropicamide and 5% phenylephrine eye drops before undergoing cataract surgery (phacoemulsification and manual small-incision surgery) under local or topical anesthesia in a medical college hospital were analyzed.
RESULTS
No untoward cardiovascular effects were seen. The increase in blood pressure after 0.8% tropicamide and 5% phenylephrine eye drops was statistically significant, but it was not relevant as it was within clinically permissible limits.
CONCLUSION
The combination of 0.8% tropicamide and 5% phenylephrine eye drops is a safe and effective option for pupillary mydriasis before cataract surgery.
目的
一项前瞻性研究，旨在评估白内障手术前用于瞳孔散大的局部用去氧肾上腺素和托吡卡胺的不良心血管效应。
方法
分析了一所医学院附属医院中517例患者的517只连续眼睛，这些患者在局部或表面麻醉下接受白内障手术（超声乳化和手法小切口手术）前常规使用0.8%托吡卡胺和5%去氧肾上腺素滴眼液。
结果
未观察到不良心血管效应。0.8%托吡卡胺和5%去氧肾上腺素滴眼液后血压升高具有统计学意义，但由于在临床允许范围内，所以无关紧要。
结论
0.8%托吡卡胺和5%去氧肾上腺素滴眼液联合使用是白内障手术前瞳孔散大的一种安全有效的选择。
Zotero 插件